Medical Oncology

Prof. Dr. Nedim Turan

Doctor and researcher Kartal Dr. Lütfi Kırdar Şehir Hastanesi İstanbul
Breast NeoplasmsLung NeoplasmsColorectal NeoplasmsCarcinoma, Non-Small-Cell LungLiver NeoplasmsPancreatic NeoplasmsHypothyroidismSkin NeoplasmsCarcinoma, HepatocellularColonic NeoplasmsCarcinoma, Renal CellCarcinomaTesticular NeoplasmsNeoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Breast Neoplasms 14 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Lung Neoplasms 7 publications
  • Colorectal Neoplasms 4 publications
  • Carcinoma, Non-Small-Cell Lung 4 publications
  • Liver Neoplasms 4 publications
  • Pancreatic Neoplasms 3 publications
  • Hypothyroidism 3 publications
  • Skin Neoplasms 2 publications
  • Carcinoma, Hepatocellular 2 publications
  • Colonic Neoplasms 2 publications
  • Carcinoma, Renal Cell 2 publications
  • Carcinoma 2 publications
  • Testicular Neoplasms 2 publications
  • Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionKartal Dr. Lütfi Kırdar Şehir Hastanesisaglik.gov.trFrom source
  • Area of workBreast NeoplasmsExtracted from 14 publications · Model version —From source
  • Publications110 publicationsOpenAlexFrom source
  • ORCID0000-0002-1140-8779ORCIDFrom source
  • Last synchronised5 November 2026 08:56https://lutfikirdareah.saglik.gov.tr/TR-1480911/doktorlarimiz.html#nedim-turansaglik.gov.tr

Scientific work

Publications on Breast Neoplasms

110 publications

  1. Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study

    Clinical Medicine Insights Oncology, 2026

    DOI 10.1177/11795549261445290 PMID 42131419 Open-access full textSource: OpenAlex

  2. Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)

    Clinical & Translational Oncology, 2026

    DOI 10.1007/s12094-026-04494-3 PMID 42400766 Source: OpenAlex

  3. Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15010386 PMID 41517635 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  4. Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15051853 PMID 41827267 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  5. Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16037-8 PMID 41987096 Open-access full textSource: OpenAlex

  6. Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma

    Journal of Cancer Research and Clinical Oncology, 2026

    DOI 10.1007/s00432-025-06411-7 PMID 41504775 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  7. Adjuvant Chemotherapy and Chemoradiotherapy in Gastric Cancer: Prognostic Determinants and Real-World Survival Outcomes

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020553 PMID 41598493 Open-access full textSource: OpenAlex

  8. Clinical Outcomes of Stage IS Non-seminomatous Germ Cell Testicular Tumors: Single-Center Experience

    Istanbul Medical Journal, 2026

    DOI 10.4274/imj.galenos.2026.62829 Open-access full textSource: OpenAlex

  9. Association Between Body Mass Index and Clinical Outcomes of CDK4/6 Inhibitors in HR+/HER2− Metastatic Breast Cancer: A Real-World Cohort Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15041671 PMID 41753358 Open-access full textSource: OpenAlex

  10. FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval

    Cancers, 2026

    DOI 10.3390/cancers18182987 PMID 42794953 Open-access full textSource: OpenAlex

View all 110 publications